Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization

Ankita Patel, Tara Shertel, Michael Wynd, Vikram Wadhera, David Serur, Benjamin Schleich, Yuriy Yushkov, Michael Goldstein

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

To describe an experience using a protocol using de novo belatacept (DNB) based maintenance immunosuppression in the setting of lymphocyte depletion. A retrospective, observational study was performed on 37 kidney transplant recipients treated with the DNB protocol, which was defined as belatacept initiated within 7 days after a kidney transplant with steroids and mycophenolate with anti-thymocyte globulin (ATG) induction without concomitant calcineurin inhibitors (CNIs). Patients who received a deceased donor kidney meeting one or more of the following criteria: anticipated cold ischemia time (CIT) greater than 24 h, donation after cardiac death, donor acute kidney injury, and a Kidney Donor Profile Index (KDPI) >85% during the study period were included. Patient survival at 1 year was 97.3% and graft survival was 94.6%. Delayed graft function (DGF) occurred in 40.54% of the patients. Two patients experienced a Banff 1B acute cellular rejection. BK viremia was detected in 32.4% of patients. The mean estimated glomerular filtration rate (eGFR) calculated with the use of modification of diet in renal disease (MDRD) equation at 1 year in the study group was 54.7 ml/min/1.73 m2. We believe that utilization of the DNB protocol, which allows early CNI avoidance, may decrease organ discard rates.

Original languageEnglish
Pages (from-to)901-905
Number of pages5
JournalNephrology
Volume27
Issue number11
DOIs
StatePublished - Nov 2022
Externally publishedYes

Keywords

  • de novo belatacept
  • immunosuppression
  • transplantation

Fingerprint

Dive into the research topics of 'Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization'. Together they form a unique fingerprint.

Cite this